Current concepts on the surgical and medical management of osteosarcoma

References

• Marcove RC, Miké V, Hajek JV, Levin AG, Hutter RV. Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases. J. Bone Joint Surg. Am.52(3), 411–423 (1970).
   PubMed Web of Science ®Google Scholar
• Jaffe N, Frei E III, Traggis D, Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N. Engl. J. Med.291(19), 994–997 (1974).
   PubMed Web of Science ®Google Scholar
• Cores EP, Holland JF, Wang JJ, Sinks LF. Doxorubicin in disseminated osteosarcoma. JAMA221(10), 1132–1138 (1972).
   Google Scholar
• Nitschke R, Starling KA, Vats T, Bryan H. Cis-diamminedichloroplatinum (NSC-119875) in childhood malignancies: a Southwest Oncology Group study. Med. Pediatr. Oncol.4(2), 127–132 (1978).
   Google Scholar
• Marti C, Kroner T, Remagen W, Berchtold W, Cserhati M, Varini M. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat. Rep.69(1), 115–117 (1985).
   PubMedGoogle Scholar
• Link MP, Goorin AM, Miser AW et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N. Engl. J. Med.314(25), 1600–1606 (1986).
   PubMed Web of Science ®Google Scholar
• Link MP, Goorin AM, Horowitz M et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin. Orthop. Relat. Res.8–14 (1991).
   Google Scholar
• Goorin AM, Harris MB, Bernstein M et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J. Clin. Oncol.20(2), 426–433 (2002).
   PubMed Web of Science ®Google Scholar
• Jeys LM, Grimer RJ, Carter SR, Tillman RM, Abudu A. Post operative infection and increased survival in osteosarcoma patients: are they associated? Ann. Surg. Oncol.14(10), 2887–2895 (2007).
   PubMed Web of Science ®Google Scholar
• Lascelles BD, Dernell WS, Correa MT et al. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Ann. Surg. Oncol.12(12), 1073–1083 (2005).
   Google Scholar
• Eilber FR, Morton DL. Immunologic studies of human sarcomas: additional evidence suggesting an associated sarcoma virus. Cancer26(3), 588–596 (1970).
   Google Scholar
• Yu A, Watts H, Jaffe N, Parkman R. Concomitant presence of tumor-specific cytotoxic and inhibitor lymphocytes in patients with osteogenic sarcoma. N. Engl. J. Med.297(3), 121–127 (1977).
   PubMed Web of Science ®Google Scholar
• MacEwen EG, Pastor J, Kutzke J et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J. Cell Biochem.92(1), 77–91 (2004).
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Snyder JS, Jaffe N. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J. Clin. Oncol.9(2), 259–267 (1991).
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo MD et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – report from the Children’s Oncology Group. J. Clin. Oncol.26(4), 633–638 (2008).
   PubMed Web of Science ®Google Scholar
• Strander H, Einhorn S. Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture. Int. J. Cancer19(4), 468–473 (1977).
   PubMed Web of Science ®Google Scholar
• Brosjö O, Bauer HC, Broström LA et al. Influence of human a-interferon on four human osteosarcoma xenografts in nude mice. Cancer Res.45(11 Pt 2), 5598–5602 (1985).
   PubMed Web of Science ®Google Scholar
• Winkler K, Beron G, Kotz R et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J. Clin. Oncol.2(6), 617–624 (1984).
   PubMed Web of Science ®Google Scholar
• Strander H. Interferons and osteosarcoma. Cytokine Growth Factor Rev.18(5–6), 373–380 (2007).
   Google Scholar
• Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood92(12), 4491–4508 (1998).
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA90(8), 3539–3543 (1993).
   PubMed Web of Science ®Google Scholar
• Kumar R, Yoneda J, Fidler IJ, Dong Z. GM-CSF-transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune-compromised mice. J. Leukoc. Biol.65(1), 102–108 (1999).
   Google Scholar
• Anderson PM, Markovic SN, Sloan JA et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin. Cancer Res.5(9), 2316–2323 (1999).
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers – a review. Gene159(1), 19–27 (1995).
   PubMed Web of Science ®Google Scholar
• Onda M, Matsuda S, Higaki S et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer77(1), 71–78 (1996).
   PubMed Web of Science ®Google Scholar
• Gorlick R, Huvos AG, Heller G et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J. Clin. Oncol.17(9), 2781–2788 (1999).
   PubMed Web of Science ®Google Scholar
• Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing’s sarcoma. Clin. Cancer Res.8(3), 788–793 (2002).
   PubMed Web of Science ®Google Scholar
• Anninga JK, van de Vijver MJ, Cleton-Jansen AM et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur. J. Cancer40(7), 963–970 (2004).
   PubMed Web of Science ®Google Scholar
• Somers GR, Ho M, Zielenska M, Squire JA, Thorner PS. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr. Dev. Pathol.8(5), 525–532 (2005).
   PubMed Web of Science ®Google Scholar
• Akatsuka T, Wada T, Kokai Y et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer94(5), 1397–1404 (2002).
   PubMed Web of Science ®Google Scholar
• Hensley ML, Maki R, Venkatraman E. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J. Clin. Oncol.20(12), 2824–2831 (2002).
   PubMed Web of Science ®Google Scholar
• Leu KM, Ostruszka LJ, Shewach D. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J. Clin. Oncol.22(9), 1706–1712 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson PM, Wiseman GA, Erlandson L. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin. Cancer Res.11(19 Pt 1), 6895–6900 (2005).
   PubMed Web of Science ®Google Scholar
• Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int. J. Cancer116(3), 458–463 (2005).
   PubMed Web of Science ®Google Scholar
• Saylors RL III, Stine KC, Sullivan J. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group Phase II study. J. Clin. Oncol.19(15), 3463–3469 (2001).
   PubMed Web of Science ®Google Scholar
• Seibel NL, Krailo M, Chen Z et al. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children’s Cancer Group (CCG) Cancer109(8), 1646–1653 (2007).
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Bradfield S, Whitlock JA. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children’s Oncology Group study. Pediatr. Blood Cancer47(6), 790–794 (2006).
   PubMed Web of Science ®Google Scholar
• Kindler HL. The pemetrexed/gemcitabine combination in pancreatic cancer. Cancer95(4 Suppl.), 928–932 (2002).
   PubMed Web of Science ®Google Scholar
• Bodmer N, Walters DK, Fuchs B. Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines. Pediatr. Blood Cancer50(4), 905–908 (2008).
   Google Scholar
• Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer104(11), 2522–2529 (2005).
   PubMed Web of Science ®Google Scholar
• Muraro M, Mereuta OM, Carraro F, Madon E, Fagioli F. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells. Cell Immunol.249(2), 63–72 (2007).
   PubMed Web of Science ®Google Scholar
• MacEwen EG, Kurzman ID, Rosenthal RC et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J. Natl Cancer Inst.81(12), 935–938 (1989).
   PubMed Web of Science ®Google Scholar
• Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res.65(6), 2406–2411 (2005).
   PubMed Web of Science ®Google Scholar
• Kawai A, Kondo T, Suehara Y, Kikuta K, Hirohashi S. Global protein-expression analysis of bone and soft tissue sarcomas. Clin. Orthop. Relat. Res. (2008) (Epub ahead of print).
   Google Scholar
• Ozaki T, Flege S, Kevric M et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J. Clin. Oncol.21(2), 334–341 (2003).
   PubMed Web of Science ®Google Scholar
• Kempf-Bielack B, Bielack SS, Jürgens H et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J. Clin. Oncol.23(3), 559–568 (2005).
   PubMed Web of Science ®Google Scholar
• DeLaney TF, Park L, Goldberg SI et al. Radiotherapy for local control of osteosarcoma. Int. J. Radiat. Oncol. Biol. Phys.61(2), 492–498 (2005).
   PubMed Web of Science ®Google Scholar
• Anderson PM. Effectiveness of radiotherapy for osteosarcoma that responds to chemotherapy. Mayo Clin. Proc.78(2), 145–146 (2003).
   PubMedGoogle Scholar
• Jaffe N, Carrasco H, Raymond K et al. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer95, 2202–2210 (2002).
   PubMed Web of Science ®Google Scholar
• Campanacci M, Laus M. Local recurrence after amputation for osteosarcoma. J. Bone Joint. Surg. Br.62-B, 201–207 (1980).
   Google Scholar
• Friedman MA, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J. Surg. Oncol.4, 482–510 (1972).
   PubMedGoogle Scholar
• Godal T. World Health Organization and health problem in developing countries. Do we have something to learn? [In Norwegian.] Tidsskr Nor Laegeforen100, 420–422 (1980).
   Google Scholar
• Ngoma T. World Health Organization cancer priorities in developing countries. Ann. Oncol.17(Suppl. 8), viii9–viii14 (2006).
   PubMedGoogle Scholar
• Kagen LB. Use of denial in adolescents with bone cancer. Health Soc. Work.1, 70–87 (1976).
   PubMedGoogle Scholar
• Felder-Puig R, Formann AK, Mildner A et al. Quality of life and psychosocial adjustment of young patients after treatment of bone cancer. Cancer83, 69–75 (1998).
   PubMed Web of Science ®Google Scholar
• Nicholson HS, Mulvihill JJ. Late effects of therapy in survivors of childhood and adolescent osteosarcoma. Cancer Treat. Res.62, 45–48 (1993).
   Google Scholar
• Agarwal M, Anchan C, Shah M et al. Limb salvage surgery for osteosarcoma: effective low-cost treatment. Clin. Orthop. Relat. Res.459, 82–91 (2007).
   PubMedGoogle Scholar
• Dillingham TR, Pezzin LE, MacKenzie EJ. Limb amputation and limb deficiency: epidemiology and recent trends in the United States. South Med. J.95, 875–883 (2002).
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J. Clin. Oncol.20, 776–790 (2002).
   PubMed Web of Science ®Google Scholar
• Ebeid W, Amin S, Abdelmegid A. Limb salvage management of pathologic fractures of primary malignant bone tumors. Cancer Control12, 57–61 (2005).
   Google Scholar
• Mankin HJ, Hornicek FJ, Rosenberg AE et al. Survival data for 648 patients with osteosarcoma treated at one institution. Clin. Orthop. Relat. Res.286–291 (2004).
   Google Scholar
• Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin. Orthop. Relat. Res.106–120 (1980).
   PubMedGoogle Scholar
• Enneking WF, Maale GE. The effect of inadvertent tumor contamination of wounds during the surgical resection of musculoskeletal neoplasms. Cancer62, 1251–1256 (1988).
   PubMedGoogle Scholar
• Bacci G, Ferrari S, Lari S et al. Osteosarcoma of the limb: amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J. Bone Joint. Surg. Br.84, 88–92 (2002).
   Google Scholar
• Ogihara Y, Sudo A, Fujinami S et al. Limb salvage for bone sarcoma of the proximal tibia. Int. Orthop.15, 377–379 (1991).
   Google Scholar
• Lindner NJ, Ramm O, Hillmann A et al. Limb salvage and outcome of osteosarcoma. The University of Muenster experience. Clin. Orthop. Relat. Res.358, 83–89 (1999).
   Google Scholar
• Eckardt JJ, Eilber FR, Rosen G et al. Endoprosthetic replacement for stage IIB osteosarcoma. Clin. Orthop. Relat. Res.207, 202–213 (1991).
   Google Scholar
• Gebhardt MC, Flugstad DI, Springfield DS et al. The use of bone allografts for limb salvage in high-grade extremity osteosarcoma. Clin. Orthop. Relat. Res.270, 181–196 (1991).
   PubMed Web of Science ®Google Scholar
• Simon MA, Aschliman MA, Thomas N, Mankin HJ. Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. 1986. J. Bone Joint Surg. Am.87, 2822 (2005).
   PubMedGoogle Scholar
• Bacci G, Ruggieri P, Bertoni F et al. Local and systemic control for osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: the Rizzoli experience. Oncol Rep.7(5), 1129–1133 (2000).
   Google Scholar
• Bacci G, Forni C, Longhi A et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J. Surg. Oncol.96(2), 118–123 (2007).
   PubMed Web of Science ®Google Scholar
• Tomer G, Cohen IJ, Kidron D et al. Prognostic factors in non-metastatic limb osteosarcoma: a 20-year experience of one center. Int. J. Oncol.15(1), 179–185 (1999).
   Google Scholar
• Virkus WW, Marshall D, Enneking WF et al. The effect of contaminated surgical margins revisited. Clin. Orthop. Relat. Res.397, 89–94 (2002).
   Google Scholar
• Khattak MJ, Umer M, Haroon-ur-Rasheed et al. Autoclaved tumor bone for reconstruction: an alternative in developing countries. Clin. Orthop. Relat. Res.447, 138–144 (2006).
   Google Scholar
• Davidson AW, Hong A, McCarthy SW, Stalley PD. En-bloc resection, extracorporeal irradiation, and re-implantation in limb salvage for bony malignancies. J. Bone Joint. Surg. Br.87(6), 851–857 (2005).
   PubMedGoogle Scholar
• Mankin HJ, Doppelt SH, Sullivan TR et al. Osteoarticular and intercalary allograft transplantation in the management of malignant tumors of bone. Cancer50, 613–630 (1982).
   PubMed Web of Science ®Google Scholar
• Clohisy DR, Mankin HJ. Osteoarticular allografts for reconstruction after resection of a musculoskeletal tumor in the proximal end of the tibia. J. Bone Joint Surg. Am.76, 549–554 (1994).
   PubMedGoogle Scholar
• Weinberg H, Kenan S, Lewis MM et al. The role of microvascular surgery in limb-sparing procedures for malignant tumors of the knee. Plast. Reconstr. Surg.92, 692–698 (1993).
   Google Scholar
• Germain MA, Dubousset J, Mascard E et al. Vascularized peroneal reconstruction after bloc resection of tumors or congenital malformations of the upper limb in children. Bull. Acad. Natl Med.184, 1671–1684; discussion 1685–1686 (2000).
   PubMed Web of Science ®Google Scholar
• Minami A, Usui M, Ogino T et al. Simultaneous reconstruction of bone and skin defects by free fibular graft with a skin flap. Microsurgery7, 38–45 (1986).
   Google Scholar
• Wittig JC, Bickels J, Wodajo F et al. Constrained total scapula reconstruction after resection of a high grade sarcoma. Clin. Orthop. Relat. Res.397, 143–155 (2002).
   Google Scholar
• Farid Y, Lin PP, Lewis VO et al. Endoprosthetic and allograft-prosthetic composite reconstruction of the proximal femur for bone neoplasms. Clin. Orthop. Relat. Res.442, 223–229 (2002).
   Google Scholar
• Jeys LM, Kulkami A, Grimes RJ et al. Endoprosthetic reconstruction for the treatment of musculoskeletal tumors of the appendicular skeleton and pelvis. J. Bone Joint Surg. Am.90(6), 1265–1271 (2008).
   PubMed Web of Science ®Google Scholar
• Reach JS Jr, Dickey ID, Zobitz ME et al. Direct tendon attachment and healing to porous tantalum: an experimental animal study. J. Bone Joint Surg. Am.89, 1000–1009 (2007).
   Google Scholar
• Wilkins RM, Soubeiran A. The Phenix expandable prosthesis: early American experience. Clin. Orthop. Relat. Res.382, 51–58 (2001).
   Google Scholar
• Gupta A, Meswania J, Pollock R et al. Non-invasive distal femoral expandable endoprosthesis for limb-salvage surgery in paediatric tumours. J. Bone Joint. Surg. Br.8, 649–654 (2006).
   Google Scholar
• Gupta A, Meswania J, Blunn G et al. Stanmore non-invasive growing arthrodesis endoprosthesis in the reconstruction of complicated total knee arthroplasty: a case report. Knee13, 247–251 (2006).
   Google Scholar
• Muller CR, Smeland S, Bauer HC, Saeter G, Strander H. Interferon-a as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol.44(5), 475–480 (2005).
   PubMed Web of Science ®Google Scholar
• Pritchard-Jones K, Spendlove I, Wilton C et al. Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. Br. J. Cancer92(8), 1358–1365 (2005).
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin. Cancer Res.13(18 Pt 2), 5549s–5555s (2007).
   PubMed Web of Science ®Google Scholar
• Kim SY, Lee CH, Midura BV et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin. Exp. Metastasis25(3), 201–211 (2008).
   PubMed Web of Science ®Google Scholar
• Kamal A, Thao L, Sensintaffar J et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature425(6956), 407–410 (2003).
   PubMed Web of Science ®Google Scholar
• Matsuyama S, Iwadate M, Kondo M et al. SB-431542 and Gleevec inhibit transforming growth factor-β-induced proliferation of human osteosarcoma cells. Cancer Res.63(22), 7791–7798 (2003).
   PubMedGoogle Scholar
• Shor AC, Keschman EA, Lee FY et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res.67(6), 2800–2808 (2007).
   PubMed Web of Science ®Google Scholar
• Biermann JS, Adkins D, Benjamin R et al. Bone cancer. J. Natl Compr. Canc. Netw.5, 420–437 (2007).
   PubMedGoogle Scholar